Evidence map›Paper›PMID 38750372›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2024

FAPI PET uptake patterns after invasive medical interventions: a single center retrospective analysis.

Peter George Maliha, Masatoshi Hotta, Andrea Farolfi, Tristan Grogan, Rejah Alano, Andrea Limon, Ethan Lam, Giuseppe Carlucci, Shadfar Bahri, Ali Salavati and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Translational Theranostics in Glioblastoma: FAPI-46 as a Precision Medicine Tool.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
  3. Non-specific uptake ofBMC cancer · 2025
    Article
  4. Review
  5. SNMMI Procedure Standard/EANM Practice Guideline for Fibroblast Activation Protein (FAP) PET.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Peter George MalihaAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA, USA. peter.maliha@mail.mcgill.ca.ORCID 0000-0002-9811-3980
Masatoshi HottaAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA, USA.
Andrea FarolfiAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA, USA.
Tristan GroganDepartment of Medicine Statistics Core, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA, USA.
Rejah AlanoAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA, USA.
Andrea LimonAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA, USA.
Ethan LamAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA, USA.
Giuseppe CarlucciAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA, USA.
Shadfar BahriAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA, USA.
Ali SalavatiAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA, USA.
Matthias BenzAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA, USA.
Daniel SilvermanAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA, USA.
Pawan GuptaAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA, USA.
Andrew QuonAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA, USA.
Martin Allen-AuerbachAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA, USA.
Johannes CzerninAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA, USA.
Jeremie CalaisAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeFibroblast activation protein (FAP)-inhibitor (FAPI)-PET tracers allow imaging of the FAP-expressing cancer associated fibroblasts (CAF) and also the normal activated fibroblasts (NAF) involved in inflammation/fibrosis that may be present after invasive medical interventions. We evaluated [68Ga]Ga-FAPI-46 uptake patterns post-medical/invasive non-systemic interventions.

methodsThis single-center retrospective analysis was conducted in 79 consecutive patients who underwent [

results163 medical/invasive interventions (mostly surgeries (49%), endoscopies (18%) and non-surgical biopsies (10%)) in 60 subjects were included for analysis. 43/163 (26%) involved FBP. FAPI uptake occurred in 24/163 (15%) of interventions (average SUVmax 3.2 (mild), range 1.5-5.1). The median time-interval post-intervention to FAPI-PET was 47.5 months and was shorter when FAPI uptake was present (median 9.5 months) than when absent (median 60.1 months; p = 0.001). Cut-off time beyond which no FAPI uptake would be present post-intervention without FBP was 8.2 months, with a sensitivity, specificity, positive predictive value and negative predictive value of 82, 90, 99 and 31% respectively. No optimal cutoff point could be determined when considering interventions with FBP. No significant difference was detected between frequency of [

conclusion[

Indexed as

Positron Emission Tomography Computed TomographyAdultAgedAged, 80 and overBiological TransportEndopeptidasesFemaleFibroblast Activation Protein AlphaHumansMaleMembrane ProteinsMiddle AgedQuinolinesRetrospective Studies68Ga-FAPIEndopeptidasesFibroblast Activation Protein AlphaMembrane ProteinsQuinolinesFAPIFibroblastInterventionPET/CTPitfall

Identifiers

PMID38750372

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.